Baxalta (NYSE: BXLT) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Baxalta to similar businesses based on the strength of its institutional ownership, analyst recommendations, earnings, profitability, dividends, risk and valuation.
Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Baxalta pays out 23.5% of its earnings in the form of a dividend. As a group, “Biopharmaceuticals” companies pay a dividend yield of 0.6% and pay out 23.5% of their earnings in the form of a dividend.
This is a summary of recent recommendations and price targets for Baxalta and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 9.23%. Given Baxalta’s rivals higher probable upside, analysts clearly believe Baxalta has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
42.7% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Baxalta and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Baxalta Competitors||$584.27 million||$101.79 million||63.78|
Baxalta’s rivals have higher revenue and earnings than Baxalta. Baxalta is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Baxalta and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Baxalta rivals beat Baxalta on 5 of the 8 factors compared.
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.